Table 1 Descriptive statistics of the cohort
n = 205 |  | Hamburg |  | Wurzburg |
|---|---|---|---|---|
n = 139 | n = 66 | |||
Patient number | Patient number | |||
Borderline tumour | Â | 17 (12%) | Â | 7 (11%) |
Recurrent ovarian cancer | Â | 20 (14%) | Â | 6 (9%) |
Primary ovarian cancer | Â | 102a (74%) | Â | 53 (80%) |
Age at diagnosis (y) | Mean (median) | 59.3 y (60 y) | Â | 56.5 y (58.5 y) |
Histological type | Serous papillary | 93 (67%) | Â | 62 (94%) |
Endometrioid | 2 (1%) | Â | 1 (2%) | |
Clear cell | 1 (0,7%) | Â | 1 (2%) | |
Müllerian mucinous | 5 (4%) |  | 2 (3%) | |
FIGO state | FIGO I-II | 2 (1%) | Â | 30 (45%) |
FIGO IIIA-IIIB | 6 (4%) | Â | 10 (15%) | |
FIGO IIIC | 69 (50%) | Â | 22 (33%) | |
FIGO IV | 17 (12%) | Â | 4 (6%) | |
Nodal involvement | Negative | 14 (10%) | Â | Â |
Positive | 54 (39%) | Â | Â | |
Grading | Low grading | 3 (2%) | Â | 19 (29%) |
High grading | 85 (61%) | Â | 47 (71%) | |
Distant metastasis | Negative | 72 (52%) | Â | 62 (94%) |
Positive | 20 (14%) | Â | 4 (6%) | |
Tumour residuum after surgery | Not macroscopically visible | 53 (38%) | Â | 33 (50%) |
< 1cm3 | 23 (17%) |  | 5 (8%) | |
> 1cm3 | 25 (18%) |  | 28 (42%) | |
Adjuvant chemotherapy | Carboplatin/Paclitaxel (Taxol) | 97 (70%) | Cyclophosphamide/Carboplatin | 10 (15%) |
Bevacizumab | 61 (43%) | Carboplatin mono | 3 (5%) | |
| Â | Â | Cyclophosphamide/Cisplatin | 36 (55%) | |
| Â | Â | None | 17 (26%) | |
Recurrence | Yes | 70 (50%) | Â | 14 (21%) |
No | 32 (23%) | Â | 35 (53%) | |
| Â | Â | Inoperable | 17 (26%) | |
Recurrence-free survival (month) | Mean (median) | 23.88 (21) | Â | 30.07 (22) |
Overall survival (month) | Mean (median) | 36 (33.5) | Â | 39.09 (19) |